PCSA

NASDAQ 已收盘

Processa Pharmaceuticals

1.56 USD
▼-0.13-7.69%
盘后 1.55 -0.64%
2026-11-20
市值
$5.23M
市盈率
—
EPS
-72.43
股息率
—
52 周区间
1.04 – 8.88
成交量
70.69K
Beta
1.23
目标价
—
52W 低 1.0452W 高 8.88
价格走势

公司简介

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta...